Chemorbit Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.40 M
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 3.54%
- Profit Growth -20.15%
- Ebitda -12.70%
- Net Worth 35.62%
- Total Assets -7.70%
About Chemorbit Lifesciences
Chemorbit Lifesciences Private Limited (CLPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 April 2019 (Five years and nine months 24 days old ). Its registered office is in Jhajjar, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Bondili Rajesh, Niraj Lakhotiya, Arun Godara, and Five other members serve as directors at the Company.
Company Details
-
Location
Jhajjar, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909HR2019PTC079652
-
Company No.
079652
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Apr 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Chemorbit Lifesciences?
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bondili Rajesh
|
Director | 09-Apr-2019 | Current |
|
Niraj Lakhotiya
|
Director | 09-Apr-2019 | Current |
|
Arun Godara
|
Director | 09-Apr-2019 | Current |
|
Ravinder Singh
|
Director | 01-Sep-2019 | Current |
|
Bhagyasri Bondili
|
Director | 01-Sep-2019 | Current |
|
Pooja Lakhotiya
|
Director | 01-Sep-2019 | Current |
Financial Performance of Chemorbit Lifesciences.
Chemorbit Lifesciences Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 3.54% increase. The company also saw a substantial fall in profitability, with a 20.15% decrease in profit. The company's net worth Soared by an impressive increase of 35.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chemorbit Lifesciences?
In 2020, Chemorbit Lifesciences had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Chemorbit International LlpBondili Rajesh, Niraj Lakhotiya and 1 more are mutual person
-
Axylus Chemicals Llp
Rakesh Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Chemorbit Lifesciences?
Unlock and access historical data on people associated with Chemorbit Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemorbit Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemorbit Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.